香港股市 將在 4 小時 7 分鐘 開市

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
6.45-0.51 (-7.33%)
收市:04:00PM EDT
6.61 +0.16 (+2.48%)
收市後: 06:19PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價6.96
開市6.95
買盤6.30 x 900
賣出價7.12 x 1000
今日波幅6.36 - 6.97
52 週波幅6.36 - 25.74
成交量1,023,526
平均成交量771,064
市值477.92M
Beta 值 (5 年,每月)-0.03
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.96
業績公佈日2023年11月06日 - 2023年11月10日
遠期股息及收益率無 (無)
除息日
1 年預測目標價37.00
  • Benzinga

    FDA Eases Partial Hold On Avidity Biosciences' Investigational Drug Study In Type Of Dystrophy

    The FDA has eased the partial clinical hold on Avidity Biosciences Inc's (NASDAQ: RNA) AOC 1001, allowing Avidity to double the number of participants in the MARINA Open-Label Extension (MARINA-OLE) study receiving 4 mg/kg of AOC 1001. The FDA is also allowing new participant enrollment for AOC 1001 at 2 mg/kg. The FDA placed a partial clinical hold on new participant enrollment in the trial in September last year. Data from the MARINA-OLE study will be used to finalize the AOC 1001 pivotal dose

  • Benzinga

    Avidity Biosciences Touts Encouraging Data From Myotonic Dystrophy Type 1 Study

    Avidity Biosciences Inc (NASDAQ: RNA) announced topline data from the Phase 1/2 MARINA trial of AOC 1001 for myotonic dystrophy type 1 (DM1). In March, the company concluded the Phase 1/2 MARINA trial with the 38 participants enrolled at 1mg/kg, 2mg/kg, and 4mg/kg of AOC 1001 and not to move forward with the 8 mg/kg dose. Directional improvement in multiple functional assessments was observed, including myotonia, strength, and mobility measures. Meaningful DMPK reduction and splicing changes in

  • Benzinga

    Why Avidity Biosciences Shares Are Sliding Today

    Avidity Biosciences Inc (NASDAQ: RNA) stock is down over 16% Thursday following its decision to conclude the Phase 1/2 MARINA trial with the 38 participants enrolled at 1mg/kg, 2mg/kg, and 4mg/kg of AOC 1001 and not to move forward with the 8 mg/kg dose in myotonic dystrophy type 1 (DM1). In September, FDA placed a partial clinical hold on new participant enrollment in the MARINA trial in response to a serious adverse event reported in a single participant in the 4mg/kg cohort. Avidity concluded